A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2013
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Mar 2012 Additional locations (Ireland, United Kingdom) added as reported by ClinicalTrials.gov.
- 20 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2009 Planned end date changed from 1 Jan 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.